Clinical Trials · NCT03951753
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 117
- Start date
- Jun 2019
- Locations
- 2 sites, Germany
- Primary endpoint
- Change From Baseline in Total Clamp Disposition Index (cDI)